Available Technologies by Category
Functionalized Nanowires for miRNA-mediated Programming of Naive T Cells
  • Technology Overview: Georgia Tech's functionalized nanowires deliver genetic materials like miRNAs and CRISPR directly to naive T cells, enhancing their therapeutic potential without pre-activation.
  • Advantages: This method preserves the naive state of T cells, allowing for better viability and functionality, reduced exhaustion, and delivery of both small and large biomolecules, including lentiviral particles.
  • Commercial Applications: The technology can be used in adoptive T cell therapy for cancer and infectious diseases, therapeutic delivery of biomolecules, and as a research tool for immune cell manipulation.
9341
Lymphoid Tissues with Switchable Protein Gradients
  • Technology Overview: Georgia Tech's hydrogel-based immune organoids mimic lymphoid tissue, enabling ex vivo differentiation of B cells and studying immune responses to infections and vaccinations.
  • Advantages: This non-invasive method supports long-term B and T cell survival, mimics antibody production processes, and offers insights into diseases like lymphoma.
  • Commercial Applications: Useful for drug discovery, clinical research on immune disorders, personalized medicine, and academic studies in immunology.
2024-116
Engineering Antigen-Specific T Cells for CAR T Cell Therapy via Antigen-Presenting Lipid Nanoparticles
  • Technology Overview: Georgia Tech's new CAR T cell therapy uses lipid nanoparticles (LNPs) to program antigen-specific T cells in vivo, potentially reducing costs and production time.

  • Advantages: This approach avoids expensive and time-consuming ex vivo manufacturing, minimizes off-target effects, can adapt to various CAR constructs and cancer types, and promises rapid scaling and reduced costs.

  • Commercial Applications: Applicable to multiple myeloma, CD19+ cancers, and a wide range of other cancers, this technology streamlines CAR T cell therapy manufacturing for faster, more affordable treatments.

9386
Lipid Nanoparticle-Mediated Delivery of mRNA Encoded Synthetic Antigens for CAR T Cell Therapy
  • Georgia Tech's novel CAR T cell therapy uses lipid nanoparticles (LNPs) to deliver mRNA-encoded synthetic antigens, improving targeting of solid tumors and reducing off-target effects.

  • The technology ensures efficient mRNA delivery, prompting tumor cells to express unique antigens, enhancing immune recognition and destruction of cancer cells.

  • This approach broadens CAR T cell therapy applicability, allows repeat dosing, and minimizes off-tumor toxicity, offering significant advantages over traditional methods.

9385
Driving Neural Activity to Rapidly Control Inflammation, Protein, and Gene Expression in the Brain
  • Novel non-invasive method utilizing neural activity to swiftly control inflammation, protein, and gene expression in the brain.
  • The technology enables rapid and precise modulation of brain functions, potentially revolutionizing treatment for various neurological conditions.
  • Commercial applications include treating Alzheimer's, schizophrenia, autism, epilepsy, and more, offering faster, non-invasive, and targeted therapeutic options.
7773
Acousto-Optical Sensors for MRI Safety Evaluation
  • The invention is an acousto-optical sensor that can measure the SAR (specific absorption rate) in its environment through temperature and the radio frequency (RF) field.
  • The innovation can be used to improve patient safety during MRI scans and to ensure MRI-compatibility for medical implants.
  • The solution is more compact and flexible than market alternatives
7953
Novel Hydrogels for Encapsulation, Vascularization, and Transplantation of Cells
  • This hydrolytically degradable poly(ethylene glycol) (PEG) hydrogel leverages ester linkages combined at various ratios with non-degradable macromers to enable tunable degradation kinetics.
  • Potential applications include controlled release and delivery of drugs or proteins as well as cell encapsulation. It can also be used as a delivery vehicle and adhesive for cells in transplantation settings.
  • These innovative hydrogels allow for rapid hydrolytic cleavage in vivo but remain stable in vitro for weeks at neural pH 7 to support regenerative medicine techniques.
9019
Low-Cost, Efficient Intracellular Delivery of Proteins and Nucleic Acids via Hydrophobic Ion Pairing
  • Safe and efficient approach of delivering therapeutics to disease by mixing cargo and charged hydrophobic ions with cells.
  • Applications in therapeutic/drug delivery, protein transduction reagent, and gene transduction reagent.
  • Enables efficacious delivery of a wide range of protein and nucleic acid therapeutics.
9178
Scalable Manufacturing Approach of Graded Polymer Thin Film Has Potential for Widespread Use
  • Combines slot die coating with a custom roll-to-roll imaging system to allow for efficient, rapid, and scalable fabrication of high-quality gradient thin films.
  • An improved manufacturing process over existing techniques because it uses broad material combinations and yields higher quality patterned thin films.
  • Incorporates multiple materials to increase the application of patterned thin films across industries, including microelectronics, energy technologies, and environmental systems.
8994
Improving Quantitative Phase Imaging to Enhance Reliability and Broaden Applications
  • Universal application of an OBM/qOBM optical phase imaging device is made possible by the optimized SNR that identifies configurations with fewer limitations (e.g., conditions, tissue).
  • The simulated SNR can identify non-intuitive geometries for optical phase imaging devices that previously may not have been identified by the arduous experimental optimization process. 
  • Optimized SNR when OBM/qOBM devices take in-vivo and in-situ measurements have been proven reliable across multiple types of tissue.
8936
Messenger RNA–Based Expression of Cardiomyocyte Phenotype Sensors and Differentiating Genes for In Vitro Correction of Cardiac Disorders
  • This invention uses a gene therapy as a direct treatment for symptomatic bradyarrhythmia and removes the needs for implantation of electronic pacemakers.
  • The innovation does not lead to spillover to the liver, spleen and lungs; allows for mRNA gene transfer to stay focal to the injection site; and does not have danger of integration into the host’s DNA.
  • The new gene therapy could be used as first-line treatment of arrhythmias and consequent ailments and to circumvent the need for major surgical interventions.
7526
Smart Nanosensor-Embedded Stent System for Wireless Surveillance of Restenosis in Coronary Artery Disease
  • An electronic stent that incorporates an ultrathin stretchable wireless sensor for continuous surveillance of restenosis along with neointimal proliferation and plaque deposition.
  • There is no existing system that offers a clinically practical solution for continuous, real- time detection of both restenosis incidence and progression.
  • This device will profoundly decrease the number of healthcare dollars spent on repeated revascularization due to restenosis in CAD.
8542
Systems and Methods for Flexible Sheath Locking with Integrated Shape Sensing
  • This technology aims to become a new steerable device to reduce the invasiveness of traditional methods for delivering drugs and diagnostic devices inside the body.
  • There are no known existing methods of delivering radiotherapy without the potential of adversely affecting healthy cells.
  • This device and method will enable drastic improvements in the quality of life of patients having to undergo radiotherapy treatment. 
9264
Enhanced Diversifying Base Editors for Directed Evolution in S. cerevisiae
  • This invention presents an optimized and integrated CRISPR diversifying base editor for use in yeast and demonstrate its ability to rapidly improve the affinity of an antibody through yeast display. 
  • The innovation has enhanced the base editor mutation rate up has been increased to 27-fold by characterizing an improved key variant and by optimizing the structure of the CRISPR guide RNAs.
  • The technology has attained a rate roughly 10-fold higher than state-of-art systems and facilitates ultra-rapid antibody diversification.
9111
Novel Repressor Proteins for Gene Regulation and CRISPRi
  • The new CRISPRi platform uses novel fusion proteins to specifically inhibit target genes of interest and overcome the off-target issues with existing CRISPR platforms already on the market.
  • The technology can be used as a life science tool and/or for diagnostics and therapeutics.
  • The platform aims to limit off-target editing, circumvent incomplete gene knockdown sgRNA sequence-dependent repression activity, and variable performance across human cancer cell lines.
9106
Microfluidic Device Enables Prediction of T-Cell Ability to Home and Engraft to Disease Tissues
  • Improve the homing capabilities of T cells to increase adoptive cell therapy treatment response and safety while decreasing off-target effects.
  • Enhance tumor-infiltrating capabilities with engineered microfluidic devices that identify optimal subsets of cells.
  • Optimize development pipelines by reducing the number of laborious in vivo studies, while also helping cell therapy companies ensure their products reach the desired tissue.
9052
mRNA Therapeutic Delivery System Offers Targeted, Sustained HIV Pre-Exposure Protection in the Female Reproductive Tract
  • This system delivers messenger RNA that encodes neutralizing antibodies, which anchor to the female reproductive tract ensuring adequate, sustained tissue concentration for HIV prophylaxis.
  • This HIV prevention therapy targets the female reproductive tract and offers month-long protection to reduce office visit frequency and potentially lower medical costs.
  • This safe, water-based technology offers ease of administration to enhance patient compliance and prevent systemic complications. 
8324
Lymphatic System-Specific Lipid Nanoparticles
  • This platform technology improves current targeting to lymphatic tissues and specifically lymphatic endothelial cells.
  • Provides superior tissue targeting and functional delivery of mRNA to lymphatics via loco-regional dermal or subcutaneous avenues.
  • mRNA-based platforms offer a transient and less immunogenic method of delivery compared to protein therapeutics or adeno-associated virus-based platforms.
9056
Soft Wireless Sternal Patch for Detecting Systemic Vasoconstriction Using Photoplethysmography
  • A wireless, soft sternal patch includes integrated skin-like, photolithographically patterned electronics specifically tuned to continuously measure vasoconstriction from the sternum.
  • In overnight trials, the device detected sleep apnea and hypopnea with 95% precision and 100% sensitivity compared to data professionally scored by licensed clinicians.
  • Use of this patch on the chest could improve detection of key markers of numerous harmful health conditions.
9170
Lymphoid Tissue System Harnesses Ex Vivo Immune Reactions for Rapid Antibody Production and Immune Response Prediction
  • This immunocompetent system uniquely accounts for the unexpected activation of various immune cells to allow proper immune cell differentiation, recapitulating an effective immune response.
  • The chemokine gradient is switchable, allowing the immune cell differentiation needed for an appropriate immune reaction.
  • An ex vivo system supports immune response creation in a controlled environment, allowing reproduction of immunologic events for developing improved therapeutics.
9196